Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation

Inclusion Criteria: Patients who meet all the criteria below * Patients aged over 20 years * Patients diagnosed with non-valvular atrial fibrillation * Patients who are treated or will be treated with rivaroxaban * Patients from whom written informed consent has been obtained Exclusion Criteria: Patients who meet any of the criteria below * The following patients in whom rivaroxaban is contraindicated for use * Patients with a history of allergies to the ingredients contained in this drug * Patients having a hemorrhagic event (intracranial hemorrhage, gastrointestinal hemorrhage or other clinically significant hemorrhagic events) * Patients having liver disease complicated with coagulation disorder or those having moderate or worse liver disorder (Grade B or C in accordance with the Child-Pugh classification) * Patients having renal failure (creatinine clearance: \<15 mL/min) * Women who are or are likely to be pregnant * Patients who are treated with HIV protease inhibitors (including ritonavir, atazanavir and indinavir) * Patients who are treated with oral or injectable formulations of azole antifungal drugs (including itraconazole, voriconazole and ketoconazole (excluding fluconazole))